Read UMR's July 13 Statement on NIH Funding in House Labor-HHS Appropriations Bill
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
NIH's Role In Sustaining the U.S. Economy | 2023 Update Now Available
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm

The first oral antiviral for treating COVID-19, Merck & Co.’s molnupiravir, received approval from the U.K. Medicines and Healthcare products Regulatory Agency on 4 November. But the approval, for people at high risk of severe disease, comes as a prominent virologist has suggested using molnupiravir could do far more harm than good, potentially unleashing new, deadlier variants of SARS-CoV-2. Other virologists say the concern is worth tracking but is largely hypothetical, for now.